3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
24
Phase 3
11
Phase 1/2
5
Phase 1
4
Phase NA
3
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
NSCLC
2
Brain Neoplasms
2
Respiratory Tract Diseases
1
Neoplasms
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Interventions
Cisplatin
6
Pemetrexed
5
Carboplatin
5
pembrolizumab
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Docetaxel
4
Gemcitabine
3
Dexamethasone
3
dexamethasone acetate
2
dexamethasone 21-phosphate
2
cemiplimab
2
auricularum
2
Specimen Handling
2
Ramucirumab
2
Radiotherapy
2
Leucovorin
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Calcium Dobesilate
2
pertuzumab
1
oblimersen
1
maimendongtang
1
endostar protein
1
cyclopropapyrroloindole
1
cediranib
1
aumolertinib
1
anamorelin
1
Vitamin B 12
1
Vinorelbine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lung Neoplasms
×
Gefitinib
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled